Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

• Status: Completed
• Trial end date: 2019-06-17
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Minoxidil

Criteria

Inclusion Criteria:

1. Only female patients are eligible

2. Patients must be 18 years of age or older

3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification

4. Patients must have been on stable birth control if premenopausal.

5. Patients are able and willing to provide written informed consent after the nature of the study is fully explained

Exclusion Criteria:

1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator

2. Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure

3. Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment

4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.

5. Patients previously having undergone hair transplant surgery prior to study entry

6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women

7. Patients who have taken spironolactone in the 3 months prior to study participation

8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed

9. Patients with ongoing infectious disease, including HIV and hepatitis

10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes

11. Patients participating in a study of an experimental drug or medical device within 30 days of study entry

12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.

13. Patients taking antiaggregating therapy

14. Patients on anticoagulant therapy

15. Patients with tendency to keloid formation

16. Patients with uncompensated diabetes

17. Patients with active skin disease or skin infection at intended treatment areas